Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors

Prostaglandins and Other Lipid Mediators

Volumn 89, Issue 3-4, 2009, Pages 140-146

  Xu, Xiaoyu ^a   Yang, Guanghui ^a   Zhang, Honglu ^a   Prestwich, Glenn D ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Angiogenesis assay; ATX; Engineered tumor xenograft; LPA antagonist; Lung cancer; Phosphonate analog; Synthetic extracellular matrix

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOTAXIN INHIBITOR; LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST; PACLITAXEL; SUNITINIB; UNCLASSIFIED DRUG;

ANGIOGENESIS; BIOENGINEERING; BREAST TUMOR; CANCER CELL; CANCER THERAPY; COLON TUMOR; DRUG ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STEREOISOMERISM; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLONIC NEOPLASMS; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; HYDROGELS; LIVER NEOPLASMS; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, NUDE; MULTIENZYME COMPLEXES; PALMITATES; PHOSPHODIESTERASE I; PHOSPHONIC ACIDS; PYROPHOSPHATASES; RECEPTORS, LYSOPHOSPHATIDIC ACID; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69549117128     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.07.006     Document Type: Review

References (69)

1. Sausville E.A., and Burger A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66 (2006) 3351-3354 [discussion 3354]
2. Liu Y., Shu X.Z., and Prestwich G.D. Tumor engineering: orthotopic cancer models in mice using cell-loaded, injectable, cross-linked hyaluronan-derived hydrogels. Tissue Eng 13 (2007) 1091-1101
3. Scaife C.L., Shea J.E., Dai Q., et al. Synthetic extracellular matrix enhances tumor growth and metastasis in an orthotopic mouse model of pancreatic adenocarcinoma. J Gastrointest Surg 12 (2008) 1074-1080
4. Zhang H., Xu X., Tsukahara R., et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor suppresses breast cancer cell migration and invasion in vitro and causes tumor regression in vivo. Cancer Res 69 (2009) 5441-5449
5. Mills G.B., and Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3 (2003) 582-591
6. Umezu-Goto M., Tanyi J., Lahad J., et al. Lysophosphatidic acid production and action: validated targets in cancer?. J Cell Biochem 92 (2004) 1115-1140
7. Federico L., Pamuklar Z., Smyth S., and Morris A. Therapeutic potential of autotaxin/lysophospholipase D inhibitors. Curr Drug Targets 9 (2008) 698-708
8. van Meeteren L., and Moolenaar W. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 46 (2007) 145-160
9. Tokumura A. Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochim Biophys Acta 1582 (2002) 18-25
10. Umezu-Goto M., Kishi Y., Taira A., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158 (2002) 227-233
11. Hecht J.H., Weiner J.A., Post S.R., and Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 135 (1996) 1071-1083
12. Schulte K.M., Beyer A., Kohrer K., Oberhauser S., and Roher H.D. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int J Cancer 92 (2001) 249-256
13. Gugger M., White R., Song S., et al. GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis Mark 24 (2008) 41-50
14. Prestwich G.D., Gajewiak J., Zhang H., Yang G., and Serban M.A. Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta 1781 (2008) 588-594
15. Jiang G., Xu Y., Fujiwara Y., et al. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. Chem Med Chem 2 (2007) 679-690
16. Wyrick B.J., Ozawa T., Lamborn K.R., Bollen A.W., and Deen D.F. Effects of Matrigel on the SF-767 malignant glioma athymic mouse tumor model. Anticancer Res 17 (1997) 2419-2425
17. Kleinman H.K., McGarvey M.L., Hassell J.R., et al. Basement membrane complexes with biological activity. Biochemistry 25 (1986) 312-318
18. Prestwich G.D. Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery. Acc Chem Res 41 (2008) 139-148
19. Allison D.D., and Grande-Allen K.J. Review Hyaluronan: a powerful tissue engineering tool. Tissue Eng 12 (2006) 2131-2140
20. Prestwich G.D. Simplifying the extracellular matrix for 3D cell culture and tissue engineering: a pragmatic approach. J Cell Biochem 101 (2007) 1370-1383
21. Prestwich G.D. Engineering a clinically useful matrix for cell therapy. Organogenesis 4 (2008) 42-47
22. Engler A.J., Sen S., Sweeney H.L., and Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 126 (2006) 677-689
23. Vanderhooft J.L., Acoutlabi M., Magda J.J., and Prestwich G.D. Rheological properties of crosslinked hyaluronan-gelatin hydrogels for tissue engineering. Macromol Biosci 9 (2008) 20-28
24. Sui M., Chen F., Chen Z., and Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 119 (2006) 712-717
25. Bikfalvi A. Angiogenesis: health and disease. Ann Oncol 17 Suppl. 10 (2006) x65-x70
26. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
27. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
28. Warren B.A., Greenblatt M., and Kommineni V.R. Tumour angiogenesis: ultrastructure of endothelial cells in mitosis. Br J Exp Pathol 53 (1972) 216-224
29. Folkman J., and Haudenschild C. Angiogenesis by capillary endothelial cells in culture. Trans Ophthalmol Soc UK 100 (1980) 346-353
30. Munaron L. Intracellular calcium, endothelial cells and angiogenesis. Recent Patents Anticancer Drug Discov 1 (2006) 105-119
31. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6 (2007) 273-286
32. Nicosia R.F., Tchao R., and Leighton J. Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. Cancer Res 43 (1983) 2159-2166
33. Kim J.S., Chang J.H., Yu H.K., et al. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 278 (2003) 29000-29008
34. Blood C.H., and Zetter B.R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1032 (1990) 89-118
35. Takano S., Kamiyama H., Tsuboi K., and Matsumura A. Angiogenesis and antiangiogenic therapy for malignant gliomas. Brain Tumor Pathol 21 (2004) 69-73
36. Rege T.A., Fears C.Y., and Gladson C.L. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neuro Oncol 7 (2005) 106-121
37. Zhou S. Combination therapy with bacteria and angiogenesis inhibitors: strangling cancer without mercy. Cancer Biol Ther 4 (2005) 846-847
38. Gulati R., and Simari R.D. Cell therapy for angiogenesis: embracing diversity. Circulation 112 (2005) 1522-1524
39. Kamiyama M., Ichikawa Y., Ishikawa T., et al. VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther 9 (2002) 197-201
40. Lim E.H., Danthi N., Bednarski M., and Li K.C. A review: integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine 1 (2005) 110-114
41. Kuhlmann M.T., Klocke R., and Nikol S. Therapeutic angiogenesis for peripheral artery disease: cytokine therapy. Vasa 36 (2007) 253-260
42. Passaniti A. Extracellular matrix-cell interactions: Matrigel and complex cellular pattern formation. Lab Invest 67 (1992) 804-808 [804; author reply]
43. Cai S., Liu Y., Zheng Shu X., and Prestwich G.D. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 26 (2005) 6054-6067
44. Hosack L., Firpo M.A., Scott J.A., Prestwich G.D., and Peattie R.A. Microvascular maturity elicited in tissue treated with cytokine-loaded hyaluronan-based hydrogels. Biomaterials 29 (2008) 2336-2347
45. Tigyi G., Dyer D.L., and Miledi R. Lysophosphatidic acid possesses dual action in cell proliferation. Proc Natl Acad Sci USA 91 (1994) 1908-1912
46. Panetti T.S., Nowlen J., and Mosher D.F. Sphingosine-1-phosphate and lysophosphatidic acid stimulate endothelial cell migration. Arterioscler Thromb Vasc Biol 20 (2000) 1013-1019
47. Piazza G.A., Ritter J.L., and Baracka C.A. Lysophosphatidic acid induction of transforming growth factors alpha and beta: modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin. Exp Cell Res 216 (1995) 51-64
48. Goetzl E.J., Kong Y., and Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 162 (1999) 2049-2056
49. Lin C.I., Chen C.N., Huang M.T., et al. Lysophosphatidic acid upregulates vascular endothelial growth factor-C and tube formation in human endothelial cells through LPA(1/3), COX-2, and NF-kappaB activation- and EGFR transactivation-dependent mechanisms. Cell Signal 20 (2008) 1804-1814
50. Rivera-Lopez C.M., Tucker A.L., and Lynch K.R. Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 11 (2008) 301-310
51. Chow L., and Eckhardt S. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25 (2007) 884-896
52. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
53. McLemore T.L., Liu M.C., Blacker P.C., et al. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res 47 (1987) 5132-5140
54. Gazdar A.F., Carney D.N., Sims H.L., and Simmons A. Heterotransplantation of small-cell carcinoma of the lung into nude mice: comparison of intracranial and subcutaneous routes. Int J Cancer 28 (1981) 777-783
55. Xu X, Prestwich GD, Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in a engineered three-dimensional lung cancer xenograft model. Cancer; in press.
56. Goudar R.K., and Vlahovic G. Hypoxia angiogenesis, and lung cancer. Curr Oncol Rep 10 (2008) 277-282
57. Sasaki T., Tanno S., Shibukawa K., et al. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts. Int J Oncol 33 (2008) 525-532
58. Murph M.M., Hurst-Kennedy J., Newton V., Brindley D.N., and Radhakrishna H. Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A-549 lung carcinoma cells. Mol Cancer Res 5 (2007) 1201-1211
59. Espey D.K., Wu X.C., Swan J., et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 110 (2007) 2119-2152
60. Ballantyne G.H., and Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 71 (1993) 4252-4266
61. Wolpin B.M., Meyerhardt J.A., Mamon H.J., and Mayer R.J. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 57 (2007) 168-185
62. Russell A.H., Tong D., Dawson L.E., and Wisbeck W. Adenocarcinoma of the proximal colon sites of initial dissemination and patterns of recurrence following surgery alone. Cancer 53 (1984) 360-367
63. Dizon D.S., and Kemeny N.E. Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol 29 (2002) 126-135
64. Silen W. Hepatic resection for metastases from colorectal carcinoma is of dubious value. Arch Surg 124 (1989) 1021-1022
65. Yang M., Zhong W., Srivastava N., et al. G-protein coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the beta-catenin pathway. Proc Natl Acad Sci USA 102 (2005) 6027-6032
66. Yun C.C., Sun H., Wang D., et al. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol Cell Physiol 289 (2005) C2-C11
67. Jackson T., Chougule M.B., Ichite N., Patlolla R.R., and Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol 63 (2008) 117-126
68. Sun L., Liang C., Shirazian S., et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46 (2003) 1116-1119
69. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337